Protagonist Therapeutics (PTGX)
(Delayed Data from NSDQ)
$53.83 USD
-0.03 (-0.06%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $53.80 -0.03 (-0.06%) 7:58 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, Protagonist Therapeutics, Inc. has a market cap of $3.34B, which represents its share price of $53.86 multiplied by its outstanding shares number of 61.98M. As a mid-cap company, PTGX's shareholders are generally exposed to less risk than shareholders of small-cap companies but more risk than large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
PTGX 53.83 -0.03(-0.06%)
Will PTGX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PTGX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PTGX
JNJ Seeks FDA Approval for Oral Psoriasis Drug Icotrokinra
Zeta (ZETA) Surges 12.6%: Is This an Indication of Further Gains?
PTGX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Tango Therapeutics (TNGX) Moves 7.5% Higher: Will This Strength Last?
J&J Oral Psoriasis Drug Meets Primary Goal in Late-Stage Study
Protagonist Therapeutics (PTGX) Reports Q1 Loss, Tops Revenue Estimates
Other News for PTGX
Deep Track Capital, LP Increases Stake in Tarsus Pharmaceuticals Inc
Insider Sell: PATEL DINESH V PH D Sells Shares of Protagonist Therapeutics Inc (PTGX)
Protagonist Therapeutics Inc (PTGX) Submits NDA for Icotrokinra to FDA | PTGX stock news
Protagonist Therapeutics, Johnson & Johnson submit icotrokinra NDA to FDA
Protagonist announces NDA submission by Johnson & Johnson for icotrokinra